North America Vaccines Market Size, Growth, Share & Trends Analysis

The North America vaccines market (excluding COVID-19) is projected to reach USD 35.68 billion by 2030 from USD 25.29 billion in 2025, at a CAGR of 7.1%. The growth of the North American vaccines market is attributed to several key factors, including the high prevalence of infectious diseases, the emphasis on preventive healthcare, and technological advancements in vaccine development.

Several key players with a strong footprint in the North America vaccines market (excluding COVID-19) include Merck & Co., Inc. (US), Pfizer, Inc. (US), GSK Plc (UK), Johnson & Johnson Services, Inc. (US), Sanofi (France), CSL (Australia), and Emergent BioSolutions (US), alongside Novavax, Inc. (US). Companies in the North American vaccines market are scaling beyond traditional vaccine production into high-throughput, automated platforms that cover advanced antigen preparation, viral vector manufacturing, mRNA synthesis, and specialized reagents for complex biologics and combination vaccine workflows. By adding new production capacity and launching integrated hardware-software ecosystems, they aim to extend regional presence, covering vaccine development programs across discovery, translational research, clinical trials, and public health applications to support precision immunization strategies.

To know about the assumptions considered for the study download the pdf brochure

In February 2024, Pfizer released positive top-line data on the season 2 efficacy of ABRYSVO, a bivalent RSV vaccine, in adults 60 and older.

Merck & Co. Inc (US)

Merck & Co., Inc. is a leading North American vaccines player, combining advanced viral vector platforms, automated fill-finish workflows, and cutting-edge manufacturing software to deliver scalable production of complex vaccines like HPV and next-generation pneumococcal formulations. By integrating new facilities in Durham, North Carolina, the company positions itself as a one-stop partner for biopharma and public health organizations needing high-volume, reliable vaccine supply to drive immunization programs.

 Pfizer, Inc. (US)

Pfizer, Inc. leads in North America vaccines through its pioneering mRNA platforms, automated lipid nanoparticle synthesis, and integrated digital supply chain analytics for rapid vaccine deployment. Recent expansions across 13 US sites and partnerships further enhance its role as a comprehensive partner for governments and healthcare systems that require agile, high-throughput vaccine manufacturing for pandemic preparedness and routine immunization.

GSK plc (UK)

GSK stands out in North America with its adjuvant systems, viral vector technologies, and automated sterile liquid vaccine production lines paired with advanced analytics software. Investments like the USD 800 million Pennsylvania expansion position GSK as a key partner for clinical researchers and public health entities seeking scalable, next-generation vaccine solutions for shingles, RSV, and influenza programs.

Market Ranking

Leading North American vaccine companies are advancing beyond traditional production into high-throughput, automated platforms that include advanced antigen preparation, viral vector manufacturing, mRNA synthesis, and specialized reagents for complex biologics and combination workflows. Merck & Co., Inc. integrates viral vector platforms and US facilities for scalable HPV/pneumococcal supply. Pfizer pioneers mRNA with 13-site expansions for agile pandemic response. GSK leverages adjuvant systems and Pennsylvania upgrades for shingles/RSV innovation. Johnson & Johnson streamlines single-dose viral vectors, while Sanofi optimizes inactivated platforms for rapid tech transfer. These integrated hardware-software ecosystems support discovery-to-deployment, positioning them as one-stop partners advancing precision immunization across biopharma and public health.

Related Reports:

North America Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR), Route of Administration (IM, SC, Oral) - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com